USOR - Virginia Oncology Associates
Welcome,         Profile    Billing    Logout  
 2 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cross, Scott
ELiPSE-1, NCT05336409: A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

Active, not recruiting
1
28
US
CNTY-101, IL-2, Lymphodepleting Chemotherapy
Century Therapeutics, Inc.
R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma
08/25
08/27
Gobhardt, Wendi
ENABLAR-2, NCT05065411: Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

Terminated
3
5
US
Enobosarm & Abemaciclib Combo, VERU-024, Verzenio, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant, exemestane, fulvestrant, exemestane plus everolimus
Veru Inc.
Metastatic Breast Cancer
10/23
01/24
PSMA-DC, NCT05939414: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Recruiting
3
450
Europe, Canada, Japan, US, RoW
AAA617, (177Lu) vipivotide tetraxetan
Novartis Pharmaceuticals
Oligometastatic Prostate Cancer (OMPC)
12/27
07/30
KEYNOTE B81, NCT04609566: Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Active, not recruiting
2
142
Canada, US
brentuximab vedotin, ADCETRIS, pembrolizumab, KEYTRUDA®
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
12/29
12/29
NUV-868-01, NCT05252390: NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Terminated
1/2
82
US, RoW
NUV-868, Olaparib, Lynparza, Enzalutamide, Xtandi
Nuvation Bio Inc.
Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasm, Pancreatic Cancer, Pancreas Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Neoplasm, Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Cancer, Castration Resistant Prostatic Neoplasms, Triple-negative Breast Cancer, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Breast Cancer, Breast Carcinoma, Cancer of Breast, Cancer of the Breast, Breast Tumor
07/24
07/24
BTX-BCI-016-PRT, NCT04875351: Breast Cancer Index (BCI) Registry

Active, not recruiting
N/A
3465
US
Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test, Breast Cancer Index (BCI) Test
Biotheranostics, Inc.
Breast Cancer
12/28
12/28
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cross, Scott
ELiPSE-1, NCT05336409: A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

Active, not recruiting
1
28
US
CNTY-101, IL-2, Lymphodepleting Chemotherapy
Century Therapeutics, Inc.
R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma
08/25
08/27
Gobhardt, Wendi
ENABLAR-2, NCT05065411: Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

Terminated
3
5
US
Enobosarm & Abemaciclib Combo, VERU-024, Verzenio, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant, exemestane, fulvestrant, exemestane plus everolimus
Veru Inc.
Metastatic Breast Cancer
10/23
01/24
PSMA-DC, NCT05939414: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Recruiting
3
450
Europe, Canada, Japan, US, RoW
AAA617, (177Lu) vipivotide tetraxetan
Novartis Pharmaceuticals
Oligometastatic Prostate Cancer (OMPC)
12/27
07/30
KEYNOTE B81, NCT04609566: Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Active, not recruiting
2
142
Canada, US
brentuximab vedotin, ADCETRIS, pembrolizumab, KEYTRUDA®
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
12/29
12/29
NUV-868-01, NCT05252390: NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Terminated
1/2
82
US, RoW
NUV-868, Olaparib, Lynparza, Enzalutamide, Xtandi
Nuvation Bio Inc.
Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasm, Pancreatic Cancer, Pancreas Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Neoplasm, Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Cancer, Castration Resistant Prostatic Neoplasms, Triple-negative Breast Cancer, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Breast Cancer, Breast Carcinoma, Cancer of Breast, Cancer of the Breast, Breast Tumor
07/24
07/24
BTX-BCI-016-PRT, NCT04875351: Breast Cancer Index (BCI) Registry

Active, not recruiting
N/A
3465
US
Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test, Breast Cancer Index (BCI) Test
Biotheranostics, Inc.
Breast Cancer
12/28
12/28

Download Options